Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $411.05, for a total transaction of $8,221,000.00. Following the transaction, the chief executive officer now owns 260,446 shares of the company’s stock, valued at $107,056,328.30. The transaction was disclosed in a filing with the SEC, which is available through this link.

TMO opened at $410.56 on Friday. The company has a current ratio of 2.62, a quick ratio of 2.02 and a debt-to-equity ratio of 0.69. The company’s fifty day moving average price is $372.71 and its two-hundred day moving average price is $334.97. Thermo Fisher Scientific Inc. has a 1-year low of $250.21 and a 1-year high of $420.99. The company has a market cap of $161.98 billion, a price-to-earnings ratio of 44.43, a PEG ratio of 1.82 and a beta of 1.04.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 22nd. The medical research company reported $3.89 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.22. The firm had revenue of $6.92 billion for the quarter, compared to the consensus estimate of $6.91 billion. Thermo Fisher Scientific had a net margin of 14.12% and a return on equity of 18.18%. During the same quarter in the prior year, the company posted $3.04 earnings per share. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 14.95 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Monday, September 14th. This represents a $0.88 annualized dividend and a dividend yield of 0.21%. Thermo Fisher Scientific’s dividend payout ratio is currently 7.13%.

Several equities analysts have issued reports on the stock. UBS Group upped their price target on shares of Thermo Fisher Scientific from $385.00 to $440.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. Argus upped their price objective on shares of Thermo Fisher Scientific from $370.00 to $450.00 in a research note on Monday. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $352.00 to $436.00 in a research note on Thursday, July 23rd. Wells Fargo & Co upped their price objective on shares of Thermo Fisher Scientific from $300.00 to $340.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 21st. Finally, Citigroup increased their target price on shares of Thermo Fisher Scientific from $390.00 to $471.00 and gave the stock a “buy” rating in a research note on Thursday, July 23rd. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $420.50.

Several hedge funds have recently made changes to their positions in the company. Capital World Investors raised its holdings in shares of Thermo Fisher Scientific by 8.0% in the first quarter. Capital World Investors now owns 16,824,726 shares of the medical research company’s stock valued at $4,771,494,000 after purchasing an additional 1,242,140 shares during the last quarter. State Street Corp raised its holdings in shares of Thermo Fisher Scientific by 1.0% in the first quarter. State Street Corp now owns 16,503,764 shares of the medical research company’s stock valued at $4,684,029,000 after purchasing an additional 165,895 shares during the last quarter. Primecap Management Co. CA raised its holdings in shares of Thermo Fisher Scientific by 2.0% in the first quarter. Primecap Management Co. CA now owns 4,845,351 shares of the medical research company’s stock valued at $1,374,142,000 after purchasing an additional 92,885 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Thermo Fisher Scientific by 0.7% in the first quarter. Wells Fargo & Company MN now owns 2,872,199 shares of the medical research company’s stock valued at $814,556,000 after purchasing an additional 18,582 shares during the last quarter. Finally, Pictet Asset Management Ltd. raised its holdings in shares of Thermo Fisher Scientific by 5.2% in the first quarter. Pictet Asset Management Ltd. now owns 2,774,089 shares of the medical research company’s stock valued at $786,732,000 after purchasing an additional 137,370 shares during the last quarter. Institutional investors own 87.51% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: What are retained earnings?

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.